Integration of a Physiologically Based Pharmacokinetic and Pharmacodynamic Model for Tegoprazan and Its Metabolite: Application for Predicting Food Effect and Intragastric pH Alterations
A physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model for tegoprazan and its major metabolite M1 was developed to predict PK and PD profiles under various scenarios. The PBPK model for tegoprazan and M1 was developed and predicted using the SimCYP<sup>®</sup> simulator...
Main Authors: | Hyeon-Cheol Jeong, Min-Gul Kim, Zhuodu Wei, Kyeong-Ryoon Lee, Jaehyeok Lee, Im-Sook Song, Kwang-Hee Shin |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-06-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/14/6/1298 |
Similar Items
-
Prediction of the Drug–Drug Interaction Potential between Tegoprazan and Amoxicillin/Clarithromycin Using the Physiologically Based Pharmacokinetic and Pharmacodynamic Model
by: Zhuodu Wei, et al.
Published: (2023-02-01) -
Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug–Drug Interactions with CYP3A4 Perpetrators
by: Lien Thi Ngo, et al.
Published: (2023-01-01) -
Ten-day tegoprazan-based concomitant therapy as a first-line treatment for Helicobacter pylori eradication
by: Yong Hwan Kwon, et al.
Published: (2023-07-01) -
Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for <i>Helicobacter pylori</i> Eradication
by: Chan Hyuk Park, et al.
Published: (2022-11-01) -
Efficacy of Tegoprazan in Patients with Laryngopharyngeal Reflux Disease: A Preliminary Feasibility Study
by: Hye Kyung Jeon, et al.
Published: (2023-09-01)